Phibro Animal Health/$PAHC
1D1W1MYTD1Y5YMAX
Capital at risk
About Phibro Animal Health
Phibro Animal Health Corp is a world-wide diversified animal health and mineral nutrition company. It strive to be a trusted partner with livestock producers, farmers, veterinarians and consumers who raise and care for farm and companion animals by providing solutions to help them maintain and enhance the health of their animals. It develop, manufacture and market products for food animals including poultry, beef and dairy cattle, swine, aquaculture and dogs. It has three segments Animal Health, Mineral Nutrition, and Performance Products. Majority of revenue comes from Animal Health segment. Animal health products are anti-bacterials, anticoccidials, nutritional specialty products, and vaccines, and vaccine adjuvants that help improve the animal's health.
- Ticker
- $PAHC
- Sector
- Health
- Primary listing
- NASDAQ
- Employees
- 2,605
- Headquarters
- Teaneck, United States
- Website
- www.pahc.com
PAHC Metrics
BasicAdvanced
$1.4B
14.66
$2.43
0.46
$0.48
1.35%
Price and volume
Market cap
$1.4B
Beta
0.46
52-week high
$60.08
52-week low
$28.25
Average daily volume
215K
Dividend rate
$0.48
Financial strength
Current ratio
2.956
Quick ratio
1.02
Long term debt to equity
195.386
Total debt to equity
206.406
Dividend payout ratio (TTM)
19.52%
Interest coverage (TTM)
4.18%
Profitability
EBITDA (TTM)
244.231
Gross margin (TTM)
33.33%
Net profit margin (TTM)
6.57%
Operating margin (TTM)
12.80%
Effective tax rate (TTM)
27.39%
Revenue per employee (TTM)
$580,000
Management effectiveness
Return on assets (TTM)
8.48%
Return on equity (TTM)
29.72%
Valuation
Price to earnings (TTM)
14.658
Price to revenue (TTM)
0.951
Price to book
3.75
Price to tangible book (TTM)
4.89
Price to free cash flow (TTM)
146.387
Free cash flow yield (TTM)
0.68%
Free cash flow per share (TTM)
0.243
Dividend yield (TTM)
1.35%
Forward dividend yield
1.35%
Growth
Revenue change (TTM)
17.12%
Earnings per share change (TTM)
104.20%
3-year revenue growth (CAGR)
15.79%
10-year revenue growth (CAGR)
7.28%
3-year earnings per share growth (CAGR)
44.52%
10-year earnings per share growth (CAGR)
1.62%
10-year dividend per share growth (CAGR)
1.84%
What the Analysts think about PAHC
Analyst ratings (Buy, Hold, Sell) for Phibro Animal Health stock.
Analyst projections of the future price of Phibro Animal Health stock.
Bulls say / Bears say
Strong FY2026 revenue growth: net sales rose 17% year-over-year to $1.518 billion, driven by Animal Health segment sales which increased 21% to $1.162 billion (Business Wire).
Margin expansion: gross margin expanded 290 basis points to 33.8% in FY2026, reflecting cost synergies and favorable product mix (Business Wire).
Confident outlook with raised FY2027 guidance: management projects adjusted diluted EPS growth of 9% to $3.41–$3.59 and net sales growth of 4%, demonstrating strategic momentum (Business Wire).
Performance Products segment sales declined 8% in FY2026 due to lower demand for personal care ingredients, highlighting segment-specific weakness (Business Wire).
High leverage ratio of 2.9x gross debt to EBITDA and modest free cash flow of $9.9 million in FY2026 may constrain financial flexibility (Business Wire).
Brazil regulatory changes banning growth-promotion antimicrobials like virginiamycin and bacitracin after a 180-day transition could reduce Animal Health segment volumes long term (Business Wire).
Data summarised monthly by Lightyear AI. Last updated on 2 Sept 2026.
PAHC Financial Performance
Revenues and expenses
PAHC Earnings Performance
Company profitability
Upcoming events
PAHC News
AllArticlesVideos
Phibro Animal Health Corporation to Participate in Morgan Stanley Annual Global Healthcare Conference
Business Wire5 days ago
Phibro Animal Health Corporation Reports Fourth Quarter and Fiscal Year Results, Provides Financial Guidance
Business Wire3 weeks ago
Phibro Animal Health Corporation to Host Webcast and Conference Call on Fourth Quarter and Fiscal Year 2026 Results
Business Wire4 weeks ago
Funds containing PAHC
AllUSDGBPEUR
Fund name | Fund size | $PAHC weighting |
|---|---|---|
iShares Nasdaq US Biotechnology$BTEC | $1.2B | 0.05% |
iShares Nasdaq US Biotechnology£BTEK | £865M | 0.05% |
iShares S&P SmallCap 600$IDP6 | $3.2B | 0.04% |
iShares MSCI USA Small Cap ESG Enhanced CTB€SXRG | €2.8B | 0.04% |
iShares MSCI USA Small Cap CTB Enhanced ESG£CUS1 | £2.4B | 0.04% |
Data displayed above is indicative only and its accuracy or completeness is not guaranteed. Actual execution price may vary. Past performance is not indicative of future results. Your return may be affected by currency fluctuations and applicable fees and charges. Capital at risk.
Real-time US market data is sourced from the IEX order book provided by Polygon. After-hours US market data is 15 minutes delayed and may differ significantly from the actual tradable price at market open.